Extracellular Vesicles as Biomarkers and Pathologic or Therapeutic Agents in Motor Neuron Diseases
A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Biological Factors".
Deadline for manuscript submissions: 20 September 2024 | Viewed by 241
Special Issue Editors
Interests: central neurotransmission; motor neuron diseases; glutamate receptors and excitotoxicity in ALS; astrocytes and microglia in ALS; bioenergetics in ALS; inflammation and oxidative stress in ALS; preclinical pharmacological and cellular treatment of ALS; molecular aspects of stress and depression; glutamate and GABA transmission in depression
Interests: molecular mechanisms of neurodegeneration; in vivo pre-clinical studies; amyotrophic lateral sclerosis; glial and neuronal primary cell cultures; glutamate excitotoxicity; glutamate receptors; synaptic nerve terminals and peri-synaptic astroglia processes; extracellular vesicles
Special Issue Information
Dear Colleagues,
Until a few years ago, extracellular vesicles (EVs) were just a mechanism for discarding non-functional cellular components. However, it became clear in the past decade that they represent potent tools for intercellular communication. This capacity is grounded on their ability to transfer proteins, lipids, and nucleic acids, affecting target cells’ physiological and pathological functions.
We now know that EVs perform numerous biological functions and are implicated in various diseases. They can be helpful as biomarkers, therapeutic agents, and vehicles for therapeutic molecules.
Although there are many areas of consensus regarding the mechanisms of EV-mediated cell-cell communication, as in any rapidly growing field, several challenges and areas of disagreement remain.
Recent studies have suggested that EV secretion and transmission are involved in the onset and progression of various neurodegenerative diseases. A growing body of evidence shows that EVs have great potential in diagnosing and treating ALS and other motor neuron diseases, representing an innovative strategy.
This special issue aims to collect a broad overview of the most advanced studies of EV research in motor neuron diseases.
Interested authors are encouraged to submit original research or review articles.
Prof. Dr. Giambattista Bonanno
Dr. Marco Milanese
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
